CiToxLAB Appoints Paul C. Barrow as Director of Scientific Projects and Client Consulting
News Jun 30, 2011
CiToxLAB, has announced that Paul C. Barrow has joined the company after serving ten years as a director of toxicology at Ricerca Biosciences.
Barrow has more than 30 years’ experience in preclinical safety testing, gained through working for the pharmaceutical industry and CROs in France, the UK and Italy.
As the director of toxicology for Ricerca, he has collaborated with more than 100 clients from the pharmaceutical, biotech, chemical and food industries to devise and execute non-clinical regulatory submission packages and to address pre- and post-marketing safety issues.
Paul is a member of the Society of Toxicology, the Teratology Society, the European Teratology Society, Eurotox and is a European Registered Toxicologist. He sits on the editorial board of the journal Reproductive Toxicology.
Over the years, Paul has published dozens of peer-reviewed papers in the field of toxicology, two textbooks and several book chapters, most recently specializing in reprotoxicology and juvenile toxicology. He has participated in test guideline working groups for the OECD and in a joint scientific consultative group for the FDA/SOT.
Paul frequently presents his work at international scientific meetings and he occasionally lectures in toxicology at schools of medicine, pharmacy and veterinary science in Guildford, Lyon, Paris, and Toulouse.
With Paul joining the company, CiToxLAB expects to further increase its attractiveness in reprotoxicology and juvenile studies. Paul C. Barrow and François Spezia, recently recruited from Chanel, Pfizer and HMR, will be working jointly to further develop those capabilities, in conjunction with Scantox, the Danish site of the newly formed group, which has internationally recognized competencies in mini-pig studies.
At CiToxLAB, Paul C. Barrow will add high-level value to clients’ projects, by providing consultancy in building studies closely tailored to clients’ needs.
The rapidly evolving needs of the biotechnology and pharmaceutical industries made CiToxLAB decide to strengthen its ability to provide clients with rapid and high value advice. This new addition is totally in line with CiToxLAB’s policy of staying close to the customer and providing excellence in service.
Sophie Baratte, managing director of CiToxLAB France, said: “I am delighted that we are adding a colleague of this standard to our organization. Paul will bring further expertise and credibility to the CIT brand that has been established over the last 40 years.”
A research team developed a microfluidic-based drug screening chip that identifies synergistic interactions between two antibiotics in eight hours. This chip can be a cell-based drug screening platform for exploring critical pharmacological patterns of antibiotic interactions, along with potential applications in screening other cell-type agents and guidance for clinical therapies.READ MORE